Dr. Rick Strassman is something of a legend in the psychedelic research community. His studies in the early 1990s re-opened a door which had been securely bolted for almost three decades: a prohibition against testing psychedelics on human research subjects.
Dr. Frederick Barrett discusses recent and upcoming studies into psilocybin — the psychoactive ingredient that puts the “magic” in magic mushrooms. This currently “Schedule 1” drug, in addition to reasonably reliably provoking mystical experiences in users, also shows promise as a therapeutic treatment for depression, PTSD, and hospice care. Dr. Barrett and colleagues at Johns Hopkins Medical Center are at the forefront of the latest research.